Ocean Biomedical, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCEA research report →
Companywww.oceanbiomedical.com
Ocean Biomedical, Inc. , a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.
- CEO
- Inderjote Kathuria
- IPO
- 2021
- Employees
- 7
- HQ
- Providence, RI, US
Price Chart
Valuation
- Market Cap
- $177.95K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -1.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 8.38%
- ROIC
- 5.95%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-3,301,000 · 0.00%
- EPS
- $-0.12 · 0.00%
- Op Income
- $0
- FCF YoY
- 55.67%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.07
- Avg Volume
- 57.34K
Get TickerSpark's AI analysis on OCEA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 14, 23 | Poseidon Bio, LLC | other | 0 |
| Feb 14, 23 | Poseidon Bio, LLC | other | 18,582,930 |
Our OCEA Coverage
We haven't published any research on OCEA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OCEA Report →